MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial carcinoma. However, the response rate is only 40–65%. This study investigated the anti-tumor effect and underlying mechanisms of the combination of cisplatin and the NEDD8-activating enzyme inhibitor MLN4924 in h...
Main Authors: | Ho, I-Lin, Kuo, Kuan-Lin, Liu, Shing-Hwa-, Chang, Hong-Chiang, Hsieh, Ju-Ton, Wu, June-Tai, Chiang, Chih-Kang, Lin, Wei-Chou, Tsai, Yu-Chieh, Chou, Chien-Tso, Hsu, Chen-Hsun, Pu, Yeong-Shiau, Shi, Chung-Sheng, Huang, Kuo-How |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655337/ |
Similar Items
-
Celecoxib-Induced Cytotoxic Effect Is Potentiated by Inhibition of Autophagy in Human Urothelial Carcinoma Cells
by: Huang, Kuo-How, et al.
Published: (2013) -
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
by: Wolenski, F S, et al.
Published: (2015) -
Broad and potent antiviral activity of the NAE inhibitor MLN4924
by: Le-Trilling, Vu Thuy Khanh, et al.
Published: (2016) -
The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
by: Malhab, Lara J. Bou, et al.
Published: (2016) -
Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
by: Yoshimine, S, et al.
Published: (2013)